Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New Therapies for Ovarian Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 May 2018

Armstrong Deborah K

Abstract excerpt

In the latest NCCN Guidelines for Ovarian Cancer, the histologic subtypes of ovarian cancer are described in more depth as they vary by frequency, typical age and disease stage at presentation, treatment recommendations, and survival probabilities. The less common subtypes are also discussed. The update with the greatest impact on the treatment of ovarian cancer, however, is probably the use of maintenance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Maintenance Chemotherapy
Share to Medical Oncology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ovariectomy

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Practice Guidelines as Topic

Share to Progression-Free Survival

Share to Societies, Medical

Source

Identifiers

PMID: 29784743
DOI: 10.6004/jnccn.2018.0034

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New Therapies for Ovarian Cancer.PMID 29784743Read ↗

New therapies for ovarian cancer.Semantic proximity Read ↗

Ovarian cancer: emerging molecular-targeted therapiesSemantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineSemantic proximity Read ↗

Current Ovarian Cancer Maintenance Strategies and Promising New DevelopmentsSemantic proximity Read ↗

Molecular/genetic therapies in ovarian cancer: future opportunities and challenges.Semantic proximity Read ↗

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future OptionsSemantic proximity Read ↗

Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer.Semantic proximity Read ↗

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?Semantic proximity Read ↗

New treatment option for ovarian cancer: PARP inhibitorsSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: A ReviewSemantic proximity Read ↗

PARP inhibitors in ovarian cancer: evidence, experience and clinical potentialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.